Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model.

ABSTRACT:

Introduction

Guideline-based therapy for Mycobacterium avium complex (MAC) pulmonary disease achieves sustained sputum conversion rates in only 43-53% of patients. Repurposing of β-lactam antibiotics such as ertapenem could expedite design of more efficacious regimens, compared to developing new drugs.

Methods

We performed an ertapenem exposure-response study in the hollow fibre system model of intracellular MAC (HFS-MAC). We recapitulated human-like intrapulmonary concentration-time profiles of eight once-daily intravenous doses of ertapenem over 28 days and performed repetitive sampling for drug concentration-time profiles and MAC burden. The % of time concentration persisted above MIC (%T_MIC) mediating either 50% or 80% of maximal effect (E₅₀, EC

SUBMITTER: Deshpande D 

PROVIDER: S-EPMC11371482 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature